Skip to main
ROIV
ROIV logo

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences Ltd demonstrates a promising outlook with its drug candidate Brepocitinib (Brepo), which has shown a significant mean total improvement score of 46.5 at week 52, indicating its potential as a highly effective treatment option. The company’s strategic focus on convenient once-daily (QD) dosing of Brepo, compared to the cumbersome intravenous immunoglobulin (IVIg) therapy, positions it favorably in a market with an existing global sales record of approximately $500 million. This combination of competitive efficacy results and improved patient compliance suggests strong market demand for Brepo and supports a positive perspective on Roivant Sciences' overall financial health and growth potential.

Bears say

Roivant Sciences Ltd. faces significant challenges due to the failure of multiple drug candidates in clinical trials, notably the IMVT assets and brepocitinib across several indications, which severely undermines investor confidence in its pipeline. The repeated failures revealed in the reports indicate a troubling trend that raises concerns about the company's ability to develop and commercialize viable treatments, further jeopardizing its financial stability. Consequently, these clinical setbacks could adversely impact revenue growth prospects and overall market performance, leading to a potentially negative outlook for the stock.

ROIV has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 8 analysts, ROIV has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.